CALIDI BIOTHERAPEUTICS INC (CLDI)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.39+2.96%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLDI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CLDI — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-07-31
Material Modification to Rights of Security Holders. Calidi Biotherapeutics, Inc., a Delaware Corporation (the “Company”), effected a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-16 (the “Reverse Stock Split”). The Reverse Stock Split was duly approved by the stockholders of the Company in its Annual Meeting of Stockholders held on June 12, 2026. Reasons for the Reverse Stock Split The Com…
Why it matters: New data can increase trust in CLD-401's potential. This may draw in investors.
Supportive ifPositive data presented at a major conference, like ASGCT or AACR.
Worry ifThere is negative or unclear data shown at these conferences.
Why it matters: The new board member's background may affect key decisions and improve operations.
Watch forThe board starts new strategies that help advance the product pipeline.
Also watch forNo clear changes in strategy or operations after the new board member joins.
Why it matters: Keeping expenses low is important for financial health. It helps fund drug development.
Supportive ifGeneral and admin costs will drop by another $1 million next quarter.
Worry ifExpenses go up or do not drop much next quarter.
Why it matters: Dosing the first patient is a key milestone for Calidi's lead drug candidate.
Supportive ifThe first patient is dosed in the Phase 1 trial for CLD-401 in Q1 2027.
Worry ifThe first patient dosing is delayed beyond Q1 2027.
Why it matters: A drop in losses would mean Calidi is cutting costs. This would help their finances.
Supportive ifOperating losses decrease from $4.4 million in Q1 2026 to below $4 million in Q2 2026.
Worry ifOperating losses go up or stay over $4.4 million in Q2 2026.
Why it matters: Better features in the RedTail platform can bring in more investors.
Supportive ifNew preclinical data on CLD-401 and CLD-501 is shown at big conferences.
Worry ifNo new data or updates on RedTail candidates are shared in the next quarter.
Why it matters: Reducing cash burn is vital for financial health. It shows better cost management.
Supportive ifCash burn rate decreases compared to Q1 2026.
Worry ifCash burn rate increases compared to Q1 2026.
Why it matters: Keeping costs down can help financial stability and boost investor trust.
Supportive ifGeneral and administrative costs go down more in Q3 2026 than in Q2 2026.
Worry ifCosts go up or stay the same, showing bad cost management.
Why it matters: Filing the IND is crucial for starting human trials. It shows progress in drug development.
Supportive ifThe company submits the IND application for CLD-401 by December 31, 2026.
Worry ifThe company delays the IND filing beyond 2026.
Why it matters: New data could show that the RedTail platform works well. This might attract investors.
Supportive ifThe company presents positive new data on CLD-501 at a major conference.
Worry ifThe company fails to present new data or presents negative results.
Why it matters: Keeping costs low is important. It helps manage cash burn and extends the company's runway.
Supportive ifThe company cuts expenses by another $1 million in Q3 2026.
Worry ifGeneral and administrative expenses go up or do not drop much.
Why it matters: Her experience could improve decisions and help advance the pipeline.
Supportive ifThe company announces a partnership or project related to Dr. Sanders' skills.
Worry ifThere is no clear change in company strategy or performance after her appointment.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$364 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $898 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,525 loss on $10,000 · 95.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.